Cyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 5,000 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $10.92, for a total transaction of $54,600.00. Following the completion of the transaction, the director now owns 806,283 shares of the company’s stock, valued at $8,804,610.36. The sale was disclosed in a filing with the SEC, which is available at this link.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total transaction of $142,650.00.
• On Thursday, March 28th, Cyrus Harmon sold 20,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.97, for a total value of $219,400.00.
• On Thursday, February 29th, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00.

Olema Pharmaceuticals Trading Up 3.1 %

Shares of NASDAQ:OLMA traded up $0.34 during mid-day trading on Tuesday, reaching $11.24. The stock had a trading volume of 670,592 shares, compared to its average volume of 775,799. The business’s 50 day moving average price is $11.44 and its 200 day moving average price is $12.84. Olema Pharmaceuticals, Inc. has a 1 year low of $5.02 and a 1 year high of $17.79. The company has a market cap of $628.65 million, a P/E ratio of -5.20 and a beta of 2.10.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.49). Analysts predict that Olema Pharmaceuticals, Inc. will post -2.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of OLMA. Susquehanna Fundamental Investments LLC acquired a new position in Olema Pharmaceuticals during the first quarter worth $176,000. Swiss National Bank boosted its position in shares of Olema Pharmaceuticals by 8.8% in the 1st quarter. Swiss National Bank now owns 70,300 shares of the company’s stock worth $796,000 after buying an additional 5,700 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Olema Pharmaceuticals by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,562 shares of the company’s stock valued at $120,000 after acquiring an additional 4,221 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Olema Pharmaceuticals during the 4th quarter valued at about $7,574,000. Finally, First Light Asset Management LLC acquired a new position in Olema Pharmaceuticals during the fourth quarter worth about $8,854,000. Institutional investors own 91.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Capital One Financial reiterated an “overweight” rating on shares of Olema Pharmaceuticals in a report on Thursday, February 22nd. Citigroup assumed coverage on Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Olema Pharmaceuticals in a research note on Tuesday, April 2nd. They set a “buy” rating and a $24.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $21.43.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.